EXPERIMENTAL STUDY OF THE ABILITY OF OLIGOPEPTIDE TRPASP-PHE-ASP TO BIND INTERLEUKIN-8

Background. One of the perspectives anticytokine therapy is development synthetic oligopeptides, which can bind and inhibit activity cytokines. The peptide, a structural analogue cytokine-binding region chemokine receptor, interest as ligand for interaction with interleukin-8 (IL-8). aim research was to evaluate Trp-Asp-Phe-Asp IL-8. Material methods. between peptide cytokine evaluated by change in IL-8 concentration, assessed enzyme immunoassay. Oligopeptide used free form adsorbed on bottom plate well immobilized polyacrylamide gel at concentration 1 µM/ml. Results. results study showed that Trp-Asp-Phe-Asp, both form, has ability maximum bound 22.13 (14.09; 30.17) pM/ml, – 4.22 (3.69; 4.75) pM/ml. reduces blood plasma 25.39 (21.34; 29.44) Conclusions. obtained are basis medical devices hemosorption order extract from human plasma.